




RealRate

PHARMACEUTICAL 2022

Mirati Therapeutics Inc
Rank 138 of 471

MIRATI
THERAPEUTICS



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Mirati Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Mirati Therapeutics Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 90% points. The greatest weakness of Mirati Therapeutics Inc is the variable Research and Development, reducing the Economic Capital Ratio by 16% points.

The company's Economic Capital Ratio, given in the ranking table, is 353%, being 78% points above the market average of 275%.

Input Variable	Value in 1000 USD
Assets, Current	1,507,983
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	143,658
Liabilities, Non-Current	48,058
Other Assets	64,947
Other Compr. Net Income	-691
Other Expenses	3,299
Other Liabilities	0
Other Net Income	-5,304
Other Revenues	72,092
Property and Equipment	15,824
Research and Development	508,594
Selling, General and Administrative Expense	136,679

Output Variable	Value in 1000 USD
Assets	1,588,754
Liabilities	191,716
Expenses	648,572
Revenues	72,092
Stockholders Equity	1,397,038
Net Income	-581,784
Comprehensive Net Income	-582,130
BaseVar	1,253,564
ECR before Limited Liability	277%
Economic Capital Ratio	353%